AI-generated analysis. Always verify with the original filing.
Cellectar Biosciences, Inc. announced financial results for the year ended December 31, 2025, reporting a net loss of $21.8 million or $8.35 per basic and diluted share, compared to $44.6 million or $36.52 per basic share in 2024. Cash and cash equivalents stood at $13.2 million as of December 31, 2025, adequate to fund basic operations into Q3 2026, alongside pipeline updates including planned CMA submission for iopofosine I 131 in Q3 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 4, 2026, we issued a press release announcing our financial results for the year ended December 31, 20
. Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated March 4, 2026, titled “Cellectar Biosciences Reports Financial Results fo
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $11.5M | GAAP |
| General and Administrative Expenses | $11.5M | GAAP |
| Total Operating Expenses | $23.0M | GAAP |
| Loss from Operations | $-23.0M | GAAP |
| Net Loss | $-21.8M | GAAP |
| Net Loss per Share - Basic | $-8.35 | GAAP |
| Net Loss per Share - Diluted | $-8.35 | GAAP |